Published in Expert Opin Drug Metab Toxicol on March 01, 2010
Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem (2011) 1.07
Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One (2011) 0.98
Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology (2012) 0.97
Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab (2012) 0.89
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol (2014) 0.87
Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology (2012) 0.85
Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn (2013) 0.84
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J (2012) 0.82
A high-throughput cell-based method to predict the unbound drug fraction in the brain. J Med Chem (2014) 0.80
Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects. Brain Res (2014) 0.78
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist. BMC Pharmacol (2010) 0.77
1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2007) 1.02
1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2010) 0.92
Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett (2011) 0.86
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos (2010) 0.85
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. J Med Chem (2008) 0.85
Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem (2010) 0.83
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem (2010) 0.80
A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template. Bioorg Med Chem Lett (2010) 0.79
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems. Bioorg Med Chem Lett (2008) 0.79
Development and validation of a high-throughput method for the quantitative analysis of D-amphetamine in rat blood using liquid chromatography/MS3 on a hybrid triple quadrupole-linear ion trap mass spectrometer and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.79
1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem (2010) 0.78
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems. Bioorg Med Chem Lett (2008) 0.78
Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies. J Med Chem (2008) 0.77
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate. Bioorg Med Chem (2013) 0.77
Novel carbazole derivatives as NPY Y1 antagonists. Bioorg Med Chem Lett (2006) 0.77
Triazolyl azabicyclo[3.1.0]hexanes: A class of potent and selective dopamine D(3) receptor antagonists. ChemMedChem (2010) 0.77
Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose. Expert Opin Drug Discov (2011) 0.76
In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem. Antimicrob Agents Chemother (2003) 0.75
Quality by design in lead optimization: a new strategy to address productivity in drug discovery. Curr Opin Pharmacol (2011) 0.75
Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization. Bioorg Med Chem Lett (2009) 0.75